These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32239529)

  • 1. Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.
    Woeste MR; Philips P; Egger ME; Scoggins CR; McMasters KM; Martin RCG
    J Surg Oncol; 2020 Jun; 121(8):1298-1305. PubMed ID: 32239529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
    Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
    J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
    Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
    Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent.
    Sipok A; Sardi A; Nieroda C; King MC; Sittig M; Gushchin V
    Int J Surg Oncol; 2018; 2018():1920276. PubMed ID: 30643644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
    Leung V; Huo YR; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C.
    Delhorme JB; Sauvinet G; Séverac F; Diab S; Liu D; Rohr S; Romain B; Brigand C
    Ann Surg Oncol; 2022 Nov; 29(12):7568-7576. PubMed ID: 35882692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
    Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
    Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
    Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
    J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure.
    de Jong LAW; Elekonawo FMK; de Reuver PR; Bremers AJA; de Wilt JHW; Jansman FGA; Ter Heine R; van Erp NP
    Br J Clin Pharmacol; 2019 Jan; 85(1):47-58. PubMed ID: 30255585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.
    Delhorme JB; Triki E; Romain B; Meyer N; Rohr S; Brigand C
    J Visc Surg; 2015 Jun; 152(3):149-54. PubMed ID: 25650364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.
    Pereira F; Serrano A; Manzanedo I; Pérez-Viejo E; González-Moreno S; González-Bayón L; Arjona-Sánchez A; Torres J; Ramos I; Barrios ME; Cascales P; Morales R; Boldó E; García-Fadrique A; Arteaga X; Gutierrez-Calvo A; Sánchez-García S; Asensio E; Ramírez CP; Artiles M; Vaqué J; Parra PA; Villarejo P; Muñoz-Casares C; Turienzo E; Calero A; Torrejimeno IJ; Prieto I; Galindo J; Borrego V; Marcello ME; Rihuete C; Carrasco J; Gomez-Quiles L
    BMC Cancer; 2022 May; 22(1):536. PubMed ID: 35549912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
    Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M
    J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
    Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C.
    Rouers A; Laurent S; Detroz B; Meurisse M
    Acta Chir Belg; 2006; 106(3):302-6. PubMed ID: 16910003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
    Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
    Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
    Cravioto-Villanueva A; Cavazos M; Luna-Perez P; Martinez-Gomez H; Ramirez ML; Solorzano J; Montiel H; Esquivel J
    Surg Today; 2016 Aug; 46(8):979-84. PubMed ID: 27138212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
    Pelz JO; Doerfer J; Dimmler A; Hohenberger W; Meyer T
    BMC Cancer; 2006 Jun; 6():162. PubMed ID: 16792796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intraperitoneal chemotherapy concentration on morbidity and survival.
    Elekonawo FMK; van Eden WJ; van der Plas WY; Ewalds RSG; de Jong LAW; Bremers AJA; Hemmer PHJ; Kok NFM; Kruijff S; Aalbers AGJ; de Reuver PR
    BJS Open; 2020 Apr; 4(2):293-300. PubMed ID: 31950702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.